448 related articles for article (PubMed ID: 8941009)
1. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
3. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract][Full Text] [Related]
4. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
5. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
8. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
10. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
12. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
13. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
14. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
15. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
16. [Value of PSA in the staging of prostatic cancer].
Sassine AM; Schulman C
Acta Urol Belg; 1992; 60(3):49-59. PubMed ID: 1283504
[TBL] [Abstract][Full Text] [Related]
17. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
18. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
19. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M
J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
[TBL] [Abstract][Full Text] [Related]
20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]